期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胸腺肽α1在非小细胞肺癌治疗中的应用 被引量：28

Effect of thymosin α1 for advanced non-small-cell lung cancer in chemotherapy patients
在线阅读 下载PDF
导出
摘要 目的:评价胸腺肽α1(Tα1)在非小细胞肺癌(NSCLC)中的作用。方法:采用随机、对照、前瞻性临床研究,共入组初治Ⅲ/Ⅳ期NSCLC40例,Tα1组:化疗+Tα1,对照组:化疗;观察两组治疗前后免疫指标变化、疗效、毒副反应、生活质量及生存率。结果:Tα1组CD4在化疗后明显高于化疗前(P<0.05),对照组NK在化疗后明显低于化疗前(P<0.05),化疗后Tα1组中性粒细胞吞噬指数显著高于对照组(P<0.05);有效率Tα1组50%(10/20),对照组35%(7/20),但差异无统计学意义(P>0.05);化疗后两组骨髓抑制无差异;Tα1组无1例发生感染或严重毒副反应,而对照组有1例严重肺部感染;Tα1组生活质量优于对照组;生存率两组有显著差异,MSTTα1组为22.1月,对照组12.0月,1年生存率Tα1组84.21%,对照组50.00%,3年生存率分别为27.72%和14.29%(P<0.05)。结论:加用Tα1的肺癌化疗可提高机体免疫力,改善生活质量,延长生存期。 Purpose:To evaluate the effects of thymosin α1 (Tα1) in chemotherapy of NSCLC. Methods:We have conducted a prospective randomized controlled clinical trial.40 non-treated cases of stage Ⅲ-Ⅳ NSCLC were randomized into Tα1 group ( chemotherapy combined with thymosin α1) and control group (chemotherapy alone). The number of T cell subgroups, the activity of NK cell and phagocytic index of neutrophilic granulocyte in peripheral blood were detected and quality of life and changes of cancer lesions were evaluated before and after treatment. Results:After treatment,the levels of CD4 in the Tα1 group was significantly higher than before treatment(P<0.05). After treatment,the natural killer(NK) activity in the control group was significantly lower than before treatment(P<0.05). After chemotherapy, phagocytic index of the Tα1 group was significantly higher than that of the control group(P<0.05).Overall response rate was 50% in the Tα1 group and 35% in the control group, but there was no statistically significant difference(P>0.05). There was no significant difference of myelosuppression between the two groups. No infections or severe toxicity occurred in the Tα1 group. One severe lung infection was seen in the control group.There was better quality of life for the Tα1 group compared with the control group(P<0.05). Prognosis of the Tα1 group was better than that of the control group. MST was 22.1 months in the Tα1 group and 12.0 months in the control group.1-year survival for the Tα1 group and the control group was 84.21% and 50.00%, respectively. 3-year survival for the Tα1 group and the control group was 27.72% and 14.29%, respectively. Conclusions:The immunological function of NSCLC is significantly elevated by Tα1 treatment. This trial indicates that chemotherapy combined with thymosin α1 for the treatment of NSCLC can improve patients’ quality of life and prolong survival.
作者 王慧敏 陈玉蓉 廖美琳 韩宝惠
机构地区 上海市胸科医院肺内科
出处 《中国癌症杂志》 CAS CSCD 2005年第3期244-247,共4页 China Oncology
关键词 胸腺肽Α1 肺癌 化疗 免疫功能 thymosin α1 lung cancer chemothyrapy immunological function
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Goldstein AL, Low TL, Mcadoo M, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide[J].Proc Natl Acad Sci USA,1977,74(2):725-729.
  • 2Knutsen AP, Freeman JJ, Mueller KR, et al. Thymosin alpha 1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelial organ coculture model[J].Int J Immunopharmacol,1999,21(1):15-26.
  • 3Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro[J].Int J Immunopharmacol,2000,22(12):1057-1066.
  • 4Ancell CD, Phipps J, Young L. Thymosin alpha-1[J].Am J Health Syst Pharm,2001,58(10):879-885.
  • 5Garaci E, Pica F, Rasi G, et al. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application[J].Int Immunopharmacol,2000,22(12):1067-1076.
  • 6Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma[J].Anticancer Res,1998,18(5A):3571-3578.
  • 7Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastasis from colorectal cancer in rats[J].Int J Cancer,1994,57(5):701-705.
  • 8Silecchia G, Guarino E, Sinibaldi-vallebona, et al. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery[J].Cancer Immunol Immunother,1999,48(4):172-178.
  • 9Moody TW, Leyton J, Zia F, et al. Thymosin alpha 1 is chemopreventive for lung adenoma formation in A/J mice[J].Cancer letter,2000,155(2):121-127.
  • 10左玉如,徐跃华.胸腺肽α1在非小细胞肺癌治疗中的免疫指标和临床观察[J].苏州大学学报（医学版）,2003,23(5):571-572. 被引量：5

二级参考文献14

  • 1HUANG Zi—cun,YANG Jian,ZHOU Jian—liang,et al(黄自存,杨健,周建良,等).Thymosin al modulate the immunity of Severe hepatitis[J].Clinical Hepatobiliary Journal(临床肝胆杂志),2000,16(2):97—99.(in Chinese).
  • 2SHI Ting—zhang,DAI Guang—hai(石廷章,戴广海).The reporte of clinical studying on I stage malignant tumor patients accepted IL-2 treatment[J].Chinese Tumor Clinical(中国肿瘤临床),1999,26(4):314—317.(in Chinese).
  • 3Francesco P,Pica F, Fmarini S,et al. Thymosin alpha one restore murune T-cell-mediated responses inhibited by in vivo cocaine adminitration [J]. Int J Immunophar-macoi,1992,14(91):18--22.
  • 4Pica F, Fraschett M, Matteucci C,et al. High dose of thymosin alpha 1 enhance the anti-tumor efficacy of combination. Chemo-immunotherapy for murine B16 melanoma [J]. Anticancer Res, 1998, 18 (5): 3571 --3576.
  • 5Eckert K,Schmitt M,Garbin F,et al. Thymosin alpha 1 effects, in vitro, on lymphokine-activated killer cells from patients with primary immunodeficiencies:preliminary results [J]. Int Immunopharmacol, 1994,16(12) :1019--1023.
  • 6GAO Zhong—du,YUAN Wei—xiang,MAO Ai—wu,et al(高中度,袁维祥,茅爱武,等).Thymosin αl influence T lymphocyte.Subsets of malignant tumor patients accepted intervene chemotherapy[J].Clinical Medicine(临床医学),2000,20(7):8—9.(in Chinese).
  • 7LU Jian—wei,ZHOU Zhen—ying,CHEN Jia,et al(陆建伟,周振英,陈嘉,等).The immunity of inalignant tumor patient accepted chemotherapyis enfluenced by Thymosin α1[J].Chinese New Medicine Journal(中国新药杂志),1999,8(12):834—836.(in Chinese).
  • 8WU Zhen—feng,WANG Tie—jun,CHI Jing—xin,et al(吴镇凤,王铁君,迟景新,等).Large dose of thymosin α1 enfluence the T hymphocyte subsets of tumor patients accepted radiotherapy[J].Chinese Journal of Immunity(中国免疫杂志),1998,14(6):438—439.(in Chinese).
  • 9Goldstein AL. Clinical applications okf thymosin alpha - 1[J]. Cancer Investigation, 1994,12 (5) : 545 - 547.
  • 10Moody TW, Fagarasan M, Zia F, et al. Thymosin alpha1 down-regulates the growth of human non - small cell lung cancer cells in vitro and in vivo [J]. Cancer Res,1993, 53(21) :5214--5218.

共引文献41

同被引文献220

引证文献28

二级引证文献143

中国癌症杂志
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部